In vivo antioxidant treatment protects against bleomycin‐induced lung damage in rats
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
This study examines the activity of the antioxidant N‐acetylcysteine on bleomycin‐induced pulmonary fibrosis in rats with emphasis on the early inflammatory phase. Rats receiving N‐acetylcysteine (300 mg kg−1 day−1, intraperitoneal) had less augmented lung wet weight, and lower levels of proteins, lactate dehydrogenase, neutrophil and macrophage counts in bronchoalveolar lavage fluid and lung myeloperoxidase activity with a betterment of histological score at 3 days postbleomycin. A diminished lung GSH/GSSG ratio and augmented lipid hydroperoxides were observed 3 days postbleomycin. These changes were attenuated by N‐acetylcysteine. Alveolar macrophages from bleomycin‐exposed rats released augmented amounts of superoxide anion and nitric oxide. N‐Acetylcysteine did not modify superoxide anion generation but reduced the increased production of nitric oxide. N‐Acetylcysteine suppressed the bleomycin‐induced increased activation of lung NF‐κ B (shift assay and immunohistochemistry), and decreased the augmented levels of the early inflammatory cytokines, tumour necrosis factor‐α, interleukin‐β, interleukin‐6 and macrophage inflammatory protein‐2 observed in bronchoalveolar lavage fluid at 1 and 3 days postbleomycin exposure. At 15 days postbleomycin, N‐acetylcysteine decreased collagen deposition in bleomycin‐exposed rats (hydroxyproline content: 6351±669 and 4626±288 μ g per lung in drug vehicle‐ and N‐acetylcysteine‐treated rats, respectively; P<0.05). Semiquantitative histological assessment at this stage showed less collagen deposition in N‐acetylcysteine‐treated rats compared to those receiving bleomycin alone. These results indicate that N‐acetylcysteine reduces the primary inflammatory events, thus preventing cellular damage and the subsequent development of pulmonary fibrosis in the bleomycin rat model. British Journal of Pharmacology (2003) 138, 1037–1048. doi:10.1038/sj.bjp.138-0705138
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Activators and target genes of Rel/NF-κB transcription factors
Pahl, H. L. (1999) · Oncogene · doi:10.1038/sj.onc.1203239 · Cited by 3,727 · cited 8×
“MIP-2 concentration was measured with an ELISA kit (rat MIP-2, Cytoscreent Biosource Int., Camarillo, CA, U.S.A.).”
BackgroundInfluential
Cited by
The NOX Family of ROS-Generating NADPH Oxidases: Physiology and Pathophysiology
Bedard, K., & Krause, K.-H. (2007) · Physiological Reviews · doi:10.1152/physrev.00044.2005 · Cited by 6,989
Moeller, A., Ask, K., Warburton, D., Gauldie, J., & Kolb, M. (2008) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2007.08.011 · Cited by 1,007
Kisseleva, T., & Brenner, D. A. (2008) · Experimental Biology and Medicine · doi:10.3181/0707-mr-190 · Cited by 503
Oxidative Stress in Pulmonary Fibrosis: A Possible Role for Redox Modulatory Therapy
Kinnula, V. L., Fattman, C. L., Tan, R. J., & Oury, T. D. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200501-017pp · Cited by 437
Molecular and cellular mechanisms of pulmonary fibrosis
Todd, N. W., Luzina, I. G., & Atamas, S. P. (2012) · Fibrogenesis & Tissue Repair · doi:10.1186/1755-1536-5-11 · Cited by 418
Metadata
- Authors
- Serrano‐Mollar, A., Closa, D., Prats, N., Blesa, S., Martinez‐Losa, M., Cortijo, J., Estrela, J. M., Morcillo, E. J., & Bulbena, O.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2003-03
- Volume
- 138
- Issue
- 6
- Pages
- 1037-1048
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W2039570259
- Cited by
- 122
- References
- 1
- FWCI
- 4.70
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.